The key catalyst is the GIST PDUFA date on Nov 30, 2026, just 25 days away. Approval would trigger a commercial launch and potential revenue inflection. Monitor FDA decision and any advisory committee activity.
Price Chart
Executive Summary
Cogent Biosciences reported Q3 2026 net loss of $111.4M, wider than the $80.9M loss in Q3 2025, driven by increased R&D and G&A spending ahead of potential FDA approvals. The company maintains a $791.1M cash balance sufficient into late 2028, with three PDUFA dates approaching: GIST (Nov 30, 2026), NonAdvSM (Dec 30, 2026), and AdvSM (June 29, 2027). No revenue or EPS consensus beat/miss is applicable as the company is pre-revenue.
Key Facts
- Net loss of $111.4M in Q3 2026 vs $80.9M in Q3 2025
- Cash, cash equivalents and marketable securities of $791.1M as of Sep 30, 2026
- R&D expenses $75.1M in Q3 2026 vs $69.0M in Q3 2025
- G&A expenses $42.1M in Q3 2026 vs $14.4M in Q3 2025
- PDUFA date for bezuclastinib in GIST: November 30, 2026
- PDUFA date for bezuclastinib in NonAdvSM: December 30, 2026
- PDUFA date for bezuclastinib in AdvSM: June 29, 2027
- Cash runway expected into late 2028, past all three PDUFA dates
Financial Impact
Net loss widened by $30.5M YoY to $111.4M; cash burn $1.2M QoQ (from $792.3M to $791.1M)
Risk Factors
- FDA non-approval or delay for bezuclastinib in GIST, NonAdvSM, or AdvSM
- Widening net losses and increasing operating expenses without revenue
- Competition from approved therapies (avapritinib, imatinib, sunitinib)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-449926 |
| Document: cogt-20261105.htm | 0001193125-26-449926 |
| Document: 0001193125-26-449926-index-headers.html | 0001193125-26-449926 |
| Document: 0001193125-26-449926-index.html | 0001193125-26-449926 |
| Document: 0001193125-26-449926.txt | 0001193125-26-449926 |
| 8-K Data (Synthetic) | 0001193125-26-449926 |
Track record
13 reports on COGT
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +17.43% at T+20 after the Jun 12, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $33.54 Now $27.44 −18.19% settles Feb 5
- Nov 5, 202611d ago 8-K Neutral 4/10 Viewing No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $31.65 Now $27.44 −13.29% settles Feb 4
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 5/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bullish 6/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Jun 12, 202622w ago Press Release Neutral 4/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- Jun 12, 202622w ago Press Release Bullish 7/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- May 30, 202624w ago Press Release Bullish 8/10 Entry $34.81 to $36.80 Now $27.44 −21.17% ▲ +5.72% +4.49% vs SPY
- May 28, 202624w ago Press Release Bullish 8/10 Entry $35.38 to $36.73 Now $27.44 −22.44% ▲ +3.82% +2.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers